Treatment & Procedure

Red light / photobiomodulation (PBM)

Biohacking

Photobiomodulation applies red and near-infrared light to skin or tissue. The number of studies is large, the certainty of results small: of 35 endpoints assessed in an umbrella review, only five reached moderate certainty of evidence.

What photobiomodulation is

Light in the range of about 630 to 850 nanometers is used. The presumed mode of action is stimulation of cytochrome c oxidase in the mitochondria, that is, an intervention in cellular energy production. It is applied as a panel, cap, probe or intraorally.

Photobiomodulation is therefore not a uniform application. Wavelength, energy density and irradiance vary so much between studies that results can hardly be transferred from one to another. In an additionally reviewed overview of chronic leg wounds, energy densities ranged from 2.4 to 126 J/cm²; of all studies, it was the one with 126 J/cm² that showed no effect, which could point to a dose reversal.

Why many studies do not add up to much certainty

Certainty of evidence according to GRADE describes how much the measured effect can be trusted. It drops when studies are prone to bias, when results scatter widely or when there are signs of publication bias, that is, signs that negative studies are published less often.

This is exactly the case with photobiomodulation. The umbrella review evaluated 15 meta-analyses with 204 randomized trials and more than 9,000 participants. 12 of the 35 endpoints were significant, and five reached moderate certainty of evidence. All other endpoints were at low or very low certainty, and publication bias was demonstrated in several analyses.

What is well supported

A primary endpoint reached in a double-blind, sham-controlled trial. In head and neck cancer patients undergoing radiotherapy, ten minutes of daily intraoral photobiomodulation reduced severe oral mucositis (WHO grade 3 or higher) from 57.1 % to 36.8 % (p=0.046). 85 participants at twelve US centers, randomized 42 versus 43, over six to eight weeks. Two weeks after the end of radiotherapy, the difference was 10.8 % versus 36.4 % (p=0.042).
Five endpoints reach moderate certainty of evidence. In the umbrella review of 15 meta-analyses, 204 RCTs and more than 9,000 participants, these are: pain in burning mouth syndrome (eSMD −0.92, 95 % CI −1.38 to −0.46), functional limitation in knee osteoarthritis (0.65, 0.14 to 1.15), fatigue in fibromyalgia (1.25, 0.63 to 1.87), hair density in androgenetic alopecia (1.32, 1.00 to 1.63) and cognitive function (0.49, 0.14 to 0.84).
The data base is broad and systematically assessed. 35 endpoints in 15 indications were assessed, using AMSTAR-2 and a modified GRADE; 12 endpoints were significant. This means more methodically processed material is available for photobiomodulation than for most other applications in this field — which is what makes separating the evidence by indication possible in the first place.
In the best-controlled application, no device-related side effects occurred. In the intraoral study, 99.5 % of sessions were completed, and there were no adverse events caused by the device — with daily use over six to eight weeks in an already burdened group.

What the studies show

Umbrella review: five of 35 endpoints

The analysis covered 15 meta-analyses on 15 indications, assessed with AMSTAR-2 and a modified GRADE approach. Moderate certainty of evidence was found for pain in burning mouth syndrome (eSMD -0.92, 95 % CI -1.38 to -0.46), functional limitation in knee osteoarthritis (0.65, 0.14 to 1.15), fatigue in fibromyalgia (1.25, 0.63 to 1.87), hair density in androgenetic alopecia (1.32, 1.00 to 1.63) and cognitive function (0.49, 0.14 to 0.84). Skin anti-aging and wound healing are expressly not among them. The review makes no statement about home devices.

Hair study: primary endpoint missed, 57 % excluded

A multicenter, randomized, double-blind and sham-controlled RCT examined 160 adults aged 18 to 65 with androgenetic alopecia over 26 weeks, 10 minutes daily with an LED cap. The primary endpoint, the change in non-vellus hair count from baseline to week 16, was not significant in the individual study arms. Only a post-hoc pooling of all three active arms – red, blue and combined – yielded plus 28.5 hairs/cm² versus sham (p=0.033). 91 of 160 participants, i.e. 57 %, were excluded from the per-protocol analysis. A single wavelength configuration is therefore not supported.

Cleanly blinded and positive: oral mucosa during radiotherapy

The methodologically most convincing positive study does not concern the skin. Randomized, double-blind and sham-controlled, 85 participants (42 versus 43) at 12 US centers received 10 minutes of daily intraoral photobiomodulation over six to eight weeks during radiotherapy for head and neck cancer. The primary endpoint, severe oral mucositis of WHO grade 3 or higher, was reached: 36.8 % versus 57.1 % (p=0.046). Two weeks after the end of radiotherapy, the figures were 10.8 % versus 36.4 % (p=0.042). No conclusion for skin, muscle, wound healing or home use can be derived from this.

Wound healing: no robust effect, at very low certainty

A meta-analysis of photobiomodulation after episiotomy included eight studies, six of them in the analysis. For pain, the SMD was 0.04 (95 % CI -0.60 to 0.68, p=0.89) with I²=91 %, for wound healing the MD was 0.94 (-0.69 to 2.56, p=0.26) with I²=94 %. According to RoB 2, only a single study had a low risk of bias, three a high one. The GRADE rating was very low for both endpoints. An overview of chronic leg wounds from six randomized trials saw a possible benefit, especially for diabetic foot ulcers, likewise at very low certainty of results.

Where the data stop

Skin anti-aging. The umbrella review expressly does not list this endpoint among the results with robust certainty.
Wound healing. In the meta-analysis after episiotomy, the effect could not be distinguished from zero either for pain or for healing, with extreme scatter between the studies. An overview of chronic leg wounds saw a possible benefit, at very low certainty of results.
The benefit of home devices. There are no robust data on whole-body panels for home use. The hair study did test an LED cap, but missed its primary endpoint.
Transferability of the mucositis results. The well-blinded positive study concerned the oral mucosa of cancer patients undergoing radiotherapy, not skin, muscle or recovery.

Status, approval and legal

The evidence reviewed contains no regulatory benefit-risk assessment. Individual devices have market clearance, for example the LED cap tested in the hair study, which is cleared in the USA for androgenetic alopecia (FDA clearance). Such a clearance certifies safety and comparability with predecessor devices, not proof of efficacy. Only the study situation can be assessed, and it has to be separated by indication: what was shown intraorally during radiotherapy says nothing about a whole-body panel in the living room.

The application is related to the medically offered water-filtered infrared A irradiation (wIRA); home panels mostly work with LEDs. This page gives no usage recommendation.

Safety

In the intraoral study with 85 participants, no device-related adverse events occurred, and 99.5 % of sessions were completed. This is a limited indication for a defined application over six to eight weeks.

A systematic problem is the dose. Energy densities in the literature range from 2.4 to 126 J/cm², and the study with the highest value showed no effect. According to these data, more light does not reliably mean more effect.

BK-Score Thin human evidence

Human evidence		5
Mechanism		5
Safety data		5
Hype gap		4
Track record of use		7

The most studies of all applications: an umbrella review of 15 meta-analyses with 204 RCTs and more than 9,000 participants (Son et al., Systematic Reviews 2025) – but no endpoint reached high certainty of results, only 5 of 35 a moderate one. Best supported is hair density in androgenetic alopecia. Core problem: wavelength, dose and irradiance vary so much that photobiomodulation is not a uniform application. Whole-body panels are marketed with longevity; what is moderately supported are individual endpoints such as hair density, knee osteoarthritis and fibromyalgia, not skin aging.

The score rates the state of knowledge, not the substance. “Safety data 9” means well studied – not harmless. “Track record of use 9” means used long and widely – that is not proof of efficacy.
Subjective assessment by Biohacking Kompakt based on published scoring rules – not a scientific rating and not a medical recommendation. Rules and all ratings (German)

Frequently asked questions about red light / photobiomodulation (PBM)

Does red light really work?

For most of the advertised purposes, this is not robustly supported. An umbrella review of fifteen meta-analyses, 204 randomized trials and more than 9,000 participants assessed thirty-five endpoints. Twelve were significant, only five reached moderate certainty of evidence. All others were at low or very low certainty, and publication bias was demonstrated in several analyses.

For which applications is photobiomodulation best supported?

Moderate certainty of evidence exists for five endpoints: pain in burning mouth syndrome, functional limitation in knee osteoarthritis, fatigue in fibromyalgia, hair density in androgenetic alopecia and cognitive function. This does not mean certainty, merely moderate confidence in the measured effect. Skin anti-aging and wound healing are expressly not among them.

Does red light help against hair loss?

The largest controlled study on this missed its primary endpoint. In 160 randomized adults over twenty-six weeks, the change in hair count was not significant in the individual study arms. The positive value of 28.5 hairs per square centimeter comes from a post-hoc pooling of all active arms, including an arm with blue light only. Fifty-seven percent of the participants were excluded from the analysis.

Do red light panels for home use do anything?

There are no robust data on whole-body panels. The large umbrella review makes no statement about home devices. The hair study tested an LED cap, and its primary endpoint was missed. Since wavelength, energy density and irradiance vary widely, study results cannot simply be transferred to a panel at home.

Is red light therapy dangerous?

No safety signals are reported from the studies reviewed. In the intraoral study with eighty-five participants, no device-related adverse events occurred and 99.5 percent of sessions were completed. This concerns a defined application over six to eight weeks and allows no general statement about other devices or longer periods.

Is there a convincing positive study?

Yes, but not for the skin. Randomized, double-blind and sham-controlled, eighty-five patients with head and neck cancer received ten minutes of light in the oral cavity daily during radiotherapy. Severe inflammation of the oral mucosa occurred in 36.8 versus 57.1 percent. This is a clinical finding during radiotherapy, not a statement about home use.

The podcast episode (in German)

Episode 76

Red light therapy: photobiomodulation in the fact check

The podcast by Paul Höser (Episode 76) · with Paul & Paula. What red and near-infrared light really does in the cell – and what distinguishes the panel from the heat cabin. Information only, no usage recommendation.

Listen on Spotify

Same categorySauna & cold (hormesis)
Same categoryNAD+ infusion
Same categoryTherapeutic plasma exchange (TPE)
Often mentioned togetherCollagen peptides
Mentioned togetherTurmeric (curcumin)
Mentioned togetherSpermidine

Sources

Open in the database – with search, filters and comparison (German app)

Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-10-04.